Abstract: Objective To explore the solution of interference in cross matching of patients with multiple myeloma treated with CD38 monoclonal antibody and to formulate its transfusion strategy.Methods Multiple myeloma patients treated with the CD38 monoclonal antibody Daratumab used dithiothreitol (DTT) before and after treatment with antibody screening cells,spectral cells,and donor red blood cells.Unexpected antibody screening,identification and cross-matching were performed by microcolumn Gel method and polybrene method respectively.Results After chemotherapy with CD38 monoclonal antibody,ABO blood groups were consistent with forward and reverse typing in 5 patients.The microcolumn Gel method was positive for antibody screening,identification and forward cross-matching,while the polybrene method was negative.Unexpected antibody screening cells,spectrum cells and donor red cells were treated with 0.2mol/L DTT.The microcolumn Gel method was negative in antibody screening,identification and forward typing.After blood transfusion,the patients' hemoglobin increased significantly,but the serum bilirubin did not change obviously.Conclusion In patients with multiple myeloma treated with CD38 monoclonal antibody,red blood cells treated with 0.2mol/L DTT can be used for antibody screening and cross matching by microcolumn Gel,or direct polybrene,which can be equally effective.

Key words: Antibody screening, Multiple myeloma, Cross match, CD38